Cargando…
Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections
Although the FDA has given emergency use authorization (EUA) for some antiviral drugs for the treatment of COVID-19, no direct antiviral drugs have been identified for the treatment of critically ill patients, the most important treatment is suppression of the hyperinflammation. The purpose of this...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343835/ https://www.ncbi.nlm.nih.gov/pubmed/35928154 http://dx.doi.org/10.3389/fmicb.2022.953328 |
_version_ | 1784761079839064064 |
---|---|
author | Yang, Liuqing Peng, Ling Wu, Weibo Cao, Mengli Chen, Chuming Wang, Fuxiang Sauver, Jennifer St. Liu, Yingxia |
author_facet | Yang, Liuqing Peng, Ling Wu, Weibo Cao, Mengli Chen, Chuming Wang, Fuxiang Sauver, Jennifer St. Liu, Yingxia |
author_sort | Yang, Liuqing |
collection | PubMed |
description | Although the FDA has given emergency use authorization (EUA) for some antiviral drugs for the treatment of COVID-19, no direct antiviral drugs have been identified for the treatment of critically ill patients, the most important treatment is suppression of the hyperinflammation. The purpose of this study was to evaluate the role of corticosteroids in hospitalized severe or critical patients positive for COVID-19. This is a retrospective single-center descriptive study. Patients classified as having severe or critical COVID-19 infections with acute respiratory dysfunction syndrome in Shenzhen Third People’s Hospital were enrolled from January 11th to March 30th, 2020. Ninety patients were classified as having severe or critical COVID-19 infections. The patients were treated with methylprednisolone with a low-to-moderate dosage and short duration. The days from the symptom onset to methylprednisolone were about 8 days. Eighteen patients were treated with invasive ventilation and intensive care unit (ICU) care. All the patients in the severe group and ten in the critical group recovered and were discharged. Three critical cases with invasive ventilation died. Although cases were much more severe in the corticosteroid-treated group, the mortality was not significantly increased. Early use of low-to-moderate dosage and short duration of corticosteroid may be the more accurate immune-modulatory treatment and brings more benefits to severe patients with COVID-19. |
format | Online Article Text |
id | pubmed-9343835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93438352022-08-03 Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections Yang, Liuqing Peng, Ling Wu, Weibo Cao, Mengli Chen, Chuming Wang, Fuxiang Sauver, Jennifer St. Liu, Yingxia Front Microbiol Microbiology Although the FDA has given emergency use authorization (EUA) for some antiviral drugs for the treatment of COVID-19, no direct antiviral drugs have been identified for the treatment of critically ill patients, the most important treatment is suppression of the hyperinflammation. The purpose of this study was to evaluate the role of corticosteroids in hospitalized severe or critical patients positive for COVID-19. This is a retrospective single-center descriptive study. Patients classified as having severe or critical COVID-19 infections with acute respiratory dysfunction syndrome in Shenzhen Third People’s Hospital were enrolled from January 11th to March 30th, 2020. Ninety patients were classified as having severe or critical COVID-19 infections. The patients were treated with methylprednisolone with a low-to-moderate dosage and short duration. The days from the symptom onset to methylprednisolone were about 8 days. Eighteen patients were treated with invasive ventilation and intensive care unit (ICU) care. All the patients in the severe group and ten in the critical group recovered and were discharged. Three critical cases with invasive ventilation died. Although cases were much more severe in the corticosteroid-treated group, the mortality was not significantly increased. Early use of low-to-moderate dosage and short duration of corticosteroid may be the more accurate immune-modulatory treatment and brings more benefits to severe patients with COVID-19. Frontiers Media S.A. 2022-07-19 /pmc/articles/PMC9343835/ /pubmed/35928154 http://dx.doi.org/10.3389/fmicb.2022.953328 Text en Copyright © 2022 Yang, Peng, Wu, Cao, Chen, Wang, Sauver and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Yang, Liuqing Peng, Ling Wu, Weibo Cao, Mengli Chen, Chuming Wang, Fuxiang Sauver, Jennifer St. Liu, Yingxia Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections |
title | Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections |
title_full | Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections |
title_fullStr | Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections |
title_full_unstemmed | Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections |
title_short | Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections |
title_sort | low-to-moderate dosage and short-term use of corticosteroids benefit patients with severe covid-19 infections |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343835/ https://www.ncbi.nlm.nih.gov/pubmed/35928154 http://dx.doi.org/10.3389/fmicb.2022.953328 |
work_keys_str_mv | AT yangliuqing lowtomoderatedosageandshorttermuseofcorticosteroidsbenefitpatientswithseverecovid19infections AT pengling lowtomoderatedosageandshorttermuseofcorticosteroidsbenefitpatientswithseverecovid19infections AT wuweibo lowtomoderatedosageandshorttermuseofcorticosteroidsbenefitpatientswithseverecovid19infections AT caomengli lowtomoderatedosageandshorttermuseofcorticosteroidsbenefitpatientswithseverecovid19infections AT chenchuming lowtomoderatedosageandshorttermuseofcorticosteroidsbenefitpatientswithseverecovid19infections AT wangfuxiang lowtomoderatedosageandshorttermuseofcorticosteroidsbenefitpatientswithseverecovid19infections AT sauverjenniferst lowtomoderatedosageandshorttermuseofcorticosteroidsbenefitpatientswithseverecovid19infections AT liuyingxia lowtomoderatedosageandshorttermuseofcorticosteroidsbenefitpatientswithseverecovid19infections |